INVENTIVA: Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress 2022

Update on Inventiva's NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by

Related Keywords

New York ,United States ,Russia ,Ukraine ,Amsterdam ,Noord Holland ,Netherlands ,Brunswick ,Niedersachsen ,Germany ,Onno Holleboom ,Inventiva Pharma ,Steven Harrison ,Aude Lepreux ,Stephen Harrison ,Sven Francque ,Michael Cooreman ,Pascaline Clerc ,Pierre Broqua ,Patricial Bank ,Hepatology Of The University Hospital Antwerp ,Brunswick Group ,Exchange Commission On ,Department Of Gastroenterology ,Nasdaq ,Pinnacle Clinical Research ,Global External Affairs ,Amsterdam University Medical Center ,International Liver Congress ,Summit Clinical Research ,Liver Congress ,Long Island City ,Euronext Paris ,Key Opinion Leaders ,Chief Scientific Officer ,Frederic Cren ,University Hospital ,Medical Director ,Summit Clinical ,Chief Medical Officer ,Principal Investigator ,Amsterdam University Medical ,Global External ,Roquet Montegon ,Private Securities Litigation Reform Act ,Universal Registration Document ,Des March ,Annual Report ,Exchange Commission ,Inventiva ,Most ,Ebcast ,Opinion ,Leaders ,Following ,Asl ,Nternational ,Liver ,Congress ,022 ,